The Problem:
- An estimated 20% of breast cancers are missed at least once by mammography, especially if the patient has dense breasts or has mucinous, lobular or rapidly growing cancers.\(^1\)
- 50% of women have dense breasts and cannot benefit from mammography alone.\(^1\)

Why Should I Use This Test In My Practice?
- BreastSentry can help you to determine if a female patient should be referred for advanced breast diagnostic procedures.
- BreastSentry provides women with additional information about breast health beyond mammography.
- Empowers women to identify breast cancers early, when they are most treatable.

The BreastSentry Solution:
- BreastSentry measures the levels of two bio-markers, proneurotensin (pro-NT) and proenkephalin (pro-ENK), which are highly predictive of a woman’s risk for developing breast cancer.
- Elevated levels of pro-NT and decreased levels of pro-ENK are strong, independent risk factors for the development of breast cancer.

The Science Behind the Test:
- Two large Swedish general population longitudinal studies were used to validate the BreastSentry test.\(^2\)-\(^{11}\)
  - The Malmo Diet and Cancer study (MDC) and the Malmo Preventive Project (MPP) found a significant predictive relationship between individual pro-NT (neurotensin) and pro-ENK (enkephalin) biomarkers and the development of breast cancer (Participants 28,098)
  - Results from the MDC study in 2012 showed a highly significant relationship between the concentration of pro-NT in the blood and the risk of developing breast cancer; the MPP study confirmed these results.

BreastSentry Patient Profile:
- The test is for any woman who needs further evaluation of breast cancer risk.
- The test should not be used on women with:
  - a personal history of breast cancer
  - a confirmed or suspected genetic mutation known to increase risk of breast cancer (e.g., BRCA)
  - a history of previous radiotherapy to the chest at a young age
  - a history of kidney disease
The Patient Benefit:

- Finding Breast Cancer early saves lives.
  - When Breast Cancer is found early, the five-year survival rate is 98%.  
  - When Breast Cancer is found late, the five-year survival rate drops to 22%.

How Do I Get Started?

1. Fill out a new account form and submit it to client relations clientrelations@myinnovativelab.com.
2. Upon completion of new account form, a starter kit(s) will be shipped based upon your testing needs.
3. Schedule training of staff through onboarding call with Innovative Diagnostic Laboratory.

What Do I do With the Results?

- Women with elevated BreastSentry scores may need to be referred for advanced imaging tests, such as breast MRI, in addition to a screening mammogram.

References:

4. Dupouy S, Mourra N, Diaw VK, et al. The potential use of the neuropeptide high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369–78